Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pioglitazone + metformin
- Development stage
- Phase 4
- Lead developer
- Forgo Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Peomet-15 is a fixed-dose combination pharmaceutical product containing pioglitazone and metformin hydrochloride, developed and marketed by Forgo Pharmaceuticals. It is indicated for the treatment of type 2 diabetes mellitus. Pioglitazone belongs to the thiazolidinedione class and acts as a potent agonist for the peroxisome proliferator-activated receptor-gamma (PPAR-γ), which regulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism, thereby improving insulin sensitivity. Metformin is a biguanide that lowers blood glucose levels by inhibiting hepatic glucose production (gluconeogenesis), decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Together, these agents provide complementary mechanisms to improve glycemic control in patients with type 2 diabetes.
- Brand names
- Peomet-15Peomet15Peomet 15
- Other names
- Pioglitazone and Metformin Hydrochloride Tablets
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on pioglitazone + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pioglitazone + metformin.